Core Viewpoint - The article discusses the challenges faced by major medical device companies, specifically Philips, GE Healthcare, and Siemens Healthineers (collectively referred to as GPS), in the Chinese market and globally due to trade wars and increasing competition. The companies are focusing on localization and adapting their strategies to navigate these challenges effectively [1][3][5]. Group 1: Market Challenges - In 2024, Philips experienced a double-digit revenue decline in the Chinese market, a trend mirrored by GE Healthcare and Siemens Healthineers [1][5]. - The trade war has significantly impacted GPS, with GE Healthcare estimating a loss of approximately $380 million due to tariffs by 2025, while Philips anticipates losses between €250 million to €300 million [4][5]. - The overall market environment is characterized by intensified competition, price pressures, and the need for strategic adaptation in response to new tariffs [5][14]. Group 2: Localization Efforts - Philips has achieved over 95% of its products being manufactured locally in China, positioning the country as a key supply chain and manufacturing hub [7][8]. - GE Healthcare emphasizes the importance of localizing every component, not just the equipment, to enhance supply chain resilience and quality [9][10]. - Both companies recognize the necessity of building local ecosystems and training talent to support their localization strategies [10][11]. Group 3: Competitive Landscape - Local Chinese companies like United Imaging, Neusoft, and Mindray are emerging as strong competitors, moving beyond imitation to innovation and price competition [14]. - The growing demand for healthcare solutions in China, driven by an aging population and increasing chronic diseases, presents ongoing market opportunities for GPS [14][15]. - The companies are adapting their strategies to focus on specific market segments rather than attempting to cover all areas, indicating a more targeted approach to competition [15].

"我回来以后，飞利浦卷起来了。公司在过去一年迎难而上，是打不死的小强的状态。" "我们都做好了准备，要打硬仗。"飞利浦大中华区总裁刘令近期对第一财经记者说。 2024年7月，刘令升任大中华区总裁之时，恰逢飞利浦在中国失速之际。这一年飞利浦在中国市场的收入出 现两位数下滑。GE医疗、西门子医疗在中国市场的境况相似。 GE医疗、飞利浦和西门子医疗（下称GPS）三家企业在中国市场集体失速。同时，他们在全球市场受到关 税战冲击，分别损失数亿美元。在全球、在中国，GPS都需要一张新的航海图。 "挑战会持续" GPS在全球医疗器械市场举足轻重，意味着逃不开贸易战的波及。 西门子医疗的总部在德国，飞利浦的总部在荷兰，GE医疗的总部在美国。美国是全球第一大医疗健康市 场，也是GPS最大单一市场。这些企业根据不同市场份量，配以不同比例的员工以及研发力量，比如西门 医疗在美国员工数量远比中国员工数量更多。 GPS在美国和欧洲都有生产制造基地，但跨大西洋的零部件和整机进出口依然频繁。这使得GPS成为关税战 的主要受影响方。 西门子医疗的第二季度财报电话会上，该公司管理层预计，美国对欧洲出口商品加征的关税可能给其全年 带来2亿至3亿 ...